Avient Corporation vs Canopy Growth Corp — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Avient Corporation is far larger — about 9.9× Canopy Growth Corp's market cap, and Avient Corporation pays a 2.42% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| AVNT | CGC | |
|---|---|---|
Market Cap | $4.17B | $421.10M |
Sector | Technology | Health |
52-Week High | $45.69 | $1.92 |
52-Week Low | $27.48 | $0.86 |
Enterprise Value | $5.62B | $378.55M |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $44.80, down 1.86% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.96 beating expectations by $0.07, marking the third consecutive earnings beat. Revenue growth of 5.8% to $917 million in Q2 2026 and improved net income margin of 5.1% reflect operational strength. Analyst consensus remains positive with 60% buy ratings and a $49.00 price target representing 9.4% upside potential.
Avient presents a favorable investment case with consistent earnings outperformance and positive analyst sentiment. The stock offers dividend income with recent $0.28 quarterly payments. Key risks include potential margin pressure from input costs and market volatility. Technical indicators show near-term overbought conditions with RSI at 78.87, suggesting possible consolidation before further upside toward the $49 consensus target.
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Trailing returns across standard periods
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →